Excess of serum copper not related to ceruloplasmin in Alzheimer disease

Neurology

Volumn 64, Issue 6, 2005, Pages 1040-1046

  Squitti, R ^a   Pasqualetti, P ^a   Dal Forno, G ^a,b   Moffa, F ^a   Cassetta, E ^a   Lupoi, D ^a   Vernieri, F ^a   Rossi, L ^c   Baldassini, M ^a   Rossini, P M ^a,b  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; CERULOPLASMIN; COPPER; PEROXIDE; TRANSFERRIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CERULOPLASMIN BLOOD LEVEL; CONTROLLED STUDY; COPPER BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; MALE; MULTIINFARCT DEMENTIA; PATHOGENESIS; PRIORITY JOURNAL;

EID: 20144371701     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000154531.79362.23     Document Type: Article

References (59)

1. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med 1997;23:134-147.
2. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001;21:4183-4187.
3. Sayre LM, Perry G, Harris PL, et al. In situ catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000;74:270-279.
4. Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper (II) to copper (I). Science 1996;271:1406-1409.
5. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999;274:37111-37116.
6. White AR, Multhaup G, Maher F, et al. The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 1999;19:9170-9179.
7. Squitti R, Cassetta E, Dal Forno G, et al. Copper perturbation in two monozygotic twins discordant for degree of cognitive impairment. Arch Neurol 2004;61:738-743.
8. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurol 2002;59:1153-1161.
9. Squitti R, Pasqualetti P, Cassetta E, et al. Elevation of serum copper levels discriminates Alzheimer's disease from vascular dementia. Neurology 2003;60:2013-2014.
10. Rossi L, Squitti R, Pasqualetti P, et al. Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. Neurosci Lett 2002;329:137-140.
11. Wirth PL, Linder M. Distribution of copper among components of human serum. J Natl Cane Inst 1985;75:277-284.
12. Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr 1996;63:797S-811S.
13. Chorsky RL, Yaghmai F, Hill WD, Stopa EG. Alzheimer's disease: a review concerning immune response and microischemia. Med Hypoth 2001;56:124-127.
14. De Luigi A, Fragiacomo C, Lucca U, et al. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev 2001;122:1985-1995.
15. Singh VK, Guthikonda P. Circulating cytokines in Alzheimer's disease. J Psychiatr Res 1997;31:657-660.
16. McKhann G, Drachman D, Folstein M, et al. Clinic diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
17. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report for the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
18. Jellinger KA. The pathology of ischemic-vascular dementia: an update. J Neurol Sci 2002;203-204:153-157.
19. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
20. Abe A, Yamashita S, Noma A. Sensitive, direct colorimetric assay for copper in serum. Clin Chem 1989;35:552-554.
21. Squitti R, Rossini PM, Cassetta E, et al. D-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 2002;32:51-59.
22. Alberti A, Bolognini L, Macciantelli D, Carratelli M. The radical cation of N,N-Diethyl-para-phenylenediamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed 2000;26:253-267.
23. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994;234:279-293.
24. Lievens M, Borque de Larrea L, Rus A. Determination of transferrin without sample predilution by a turbidimetric assay on Boehringer Mannheim/Hitachi analysis systems. Lab Med 1994;18:83-90.
25. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965;2:235-243.
26. Hixson JE, Vernier DT. Restriction isotyping of human APOE by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
27. Leroux-Roels G, Offner F, Philippe J, Vermeulen A. Influence of blood-collecting systems on concentrations of tumor-necrosis factor in serum and plasma. Clin Chem 1988;34:2373-2374.
28. Dinarello CA. An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol 1985;5:287-297.
29. Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 1996;36:378-384.
30. Orsini A, Chiacchio L, Cinque M, et al. Effects of age, education and sex on two tests of immediate memory: a study of normal subjects from 20 to 99 years of age. Percept Mot Skills 1986;63:727-732.
31. Scheltens P, Launer LJ, Barkhof F, et al. Visual assessment of medial temporal lobe atrophy on magnetic resonance reliability. J Neurol 1995; 242:557-560.
32. Scheltens P, Erkinjunti T, Leys D, et al. White matter changes on CT and MRI: an overview of visual rating scales. Eur Neurol 1998;39:80-89.
33. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-972.
34. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trial. J Neural Transm 2000; 59(suppl):23-30.
35. Bartels E, ed. Color-coded duplex ultrasonography of the cerebral vessels: atlas and manual. Stuttgart: Schattauer, 1999.
36. O'Leary DH, Polak F, Kronmal RA, et al. Carotid-artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Group. N Engl J Med 1999;340:14-22.
37. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J Neurosurg 1982;57:769-774.
38. Johnson PE, Milne DB, Ikken GI. Effects of age and sex on copper absorption, biological half-life, and status in humans. Am J Clin Nutr 1992;56:917-925.
39. Snaedal J, Kristinsson J, Gunnarsdottier S, et al. Copper ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease, a case-control study. Dement Geriatr Cogn Disord 1998;9:239.
40. Brenner S. Elevation of serum copper levels in Alzheimer's disease. Neurology 2003;60:1559. Letter.
41. Gonzàlez C, Martin T, Cacho J, et al. Serum zinc, copper, insulin, and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 1999;29:637-642.
42. Molina JA, Jimenez-Jimenez FJ, Aguilar MV, et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm 1998;105:479-488.
43. Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J 2002;43:28-32.
44. Gubler CJ, Lahey ME, Cartwright GE, Wirtrobe MM. Studies of copper metabolism. IX The transportation of copper in the blood. J Clin Invest 1953;32:404-414.
45. White AR, Reyes R, Mercer JF, et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 1999;842:439-444.
46. Bush AI, Masters CL, Tanzi RE. Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc Natl Acad Sci USA 2003; 100:11193-11194.
47. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003;26:207-214.
48. Maynard CJ, Cappai R, Volitakis I, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002;277:44670-44676.
49. Hartter DE, Barnea A. Brain tissue accumulates copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process. J Biol Chem 1988;263:799-805.
50. Scheinberg IH, Sternlieb I. Wilson disease. In: Scheinberg IH, Sternlieb I, eds. Philadelphia: WB Saunders, 1984; 25-37.
51. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 2002;23:1031-1038.
52. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 2003;100:11065-11069.
53. Corbo RM, Scacchi R, Mureddu L, et al. Apolipoprotein E polymorphism in Italy investigated in native plasma by a simple polyacrylamide gel isoelectric focusing technique. Comparison with frequency data of other European populations. Ann Hum Genet 1995;59:197-209.
54. Panza F, Colacicco AM, Basile AM, et al. Impact of decreased frequency of apolipoprotein E varepsilon4 allele on Alzheimer's disease in Southern Italy. Arch Gerontol Geriatr 2001;33 suppl 1:299-306.
55. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995;37:596-604.
56. Scacchi R, De Bernardini L, Mantuano E, et al. Apolipoprotein E (APOE) allele frequencies in late-onset sporadic Alzheimer's disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. Neurosci Lett 1995;201:231-234.
57. De la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152.
58. De La Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann NY Acad Sci 2002;977:196-215.
59. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414:212-216.